Jefferies raised the firm’s price target on Hims & Hers to $23 from $14 and keeps a Hold rating on the shares. The firm assumes shortages abate in 4Q25 and IP issues begin to impact the business at the end of calendar 2025, the analyst tells investors in a research note. Jefferies says website traffic has moderated after an initial surge, and shares are pricing in upside with limited consideration of long-term potential for IP-related issues.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims and Hers Health call volume above normal and directionally bullish
- Hims & Hers price target raised to $26 from $22 at BofA
- Hims & Hers price target raised to $22 from $17.25 at BofA
- Unusually active option classes on open May 31st
- Hims & Hers price target raised to $26 from $24 at Seaport Research